

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Gheuens Sarah</u> (Last) (First) (Middle) 88 SIDNEY STREET (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 09/01/2021	3. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS, INC. [AGIO]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Medical Officer	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common stock	3,462	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock option (right to buy)	(1)	12/02/2029	Common stock	6,044	38.72	D	
Restricted stock units	(2)	(2)	Common stock	1,667	(3)	D	
Restricted stock units	(4)	(4)	Common stock	6,486	(3)	D	
Restricted stock units	(5)	(5)	Common stock	9,375	(3)	D	
Stock option (right to buy)	(6)	02/10/2031	Common stock	3,243	56.68	D	

Explanation of Responses:

- This option was granted on December 2, 2019. The shares underlying this option vest as to 25% of the underlying shares on December 2, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- The restricted stock units were granted on December 2, 2019. Beginning on December 2, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.
- Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments.
- The restricted stock units were granted on December 23, 2020. The shares underlying the restricted stock units will vest in full on December 23, 2022.
- This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Remarks:

/s/ William Cook, as attorney-in-fact for Sarah Gheuens 09/10/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of James Burns and William Cook, signing singly as

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Agios Pharmaceuticals, Inc
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute
- (3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney in fact, may be of

The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of August, 2021.

Signature:

/s/ Sarah Gheuens

Print Name:

Sarah Gheuens